Research programme: antiarrhythmic agents - sanofi-aventis

Drug Profile

Research programme: antiarrhythmic agents - sanofi-aventis

Alternative Names: SAR114646; SAR114646A

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Developer Sanofi
  • Class Antiarrhythmics
  • Mechanism of Action L-type calcium channel antagonists; Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Arrhythmias

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Arrhythmias in France (IV)
  • 03 Sep 2008 Pharmacodynamics data from preclinical trials in Arrhythmias presented at the ESC Congress 2008: Annual Congress of the European Society of Cardiology (ESC-2008) ,
  • 01 Jun 2006 Preclinical trials in Arrhythmias in France (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top